Skip to main content
Clinical Trials/NCT01081418
NCT01081418
Completed
Phase 4

Assertive Community Treatment (ACT) as Part of Integrated Care Versus Standard Care: a 12-month Trial in Patients With First- and Negatively Selected Multiple-episode Schizophrenia-spectrum Disorders Treated With Quetiapine IR

Universitätsklinikum Hamburg-Eppendorf1 site in 1 country120 target enrollmentApril 2005
ConditionsSchizophrenia

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Enrollment
120
Locations
1
Primary Endpoint
Time to Service Disengagement
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

The study examined the 12-month effectiveness of continuous therapeutic assertive community treatment (ACT) as part of integrated care (IC) compared to standard care (SC) in a catchment area comparison design in patients with schizophrenia spectrum disorders (SSD) treated with quetiapine IR.

Detailed Description

Two catchment areas in Hamburg, Germany with similar population size and health care structures were assigned to offer 12-month ACT (\& IC; Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf) or SC (Asklepios Hospital, Department of Psychiatry and Psychotherapy) to 120 first-episode and negatively selected multiple-episode patients with SSD. Primary outcome was the time to Service Disengagement. Secondary outcomes comprised medication non-adherence, improvements of symptoms, functioning, quality of life, satisfaction with care from patients and relatives perspectives, and service use data.

Registry
clinicaltrials.gov
Start Date
April 2005
End Date
April 2009
Last Updated
16 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age 18-65 years
  • Met the diagnostic criteria of a first- or multiple episode of a schizophrenia spectrum disorders, i.e. schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, or psychotic disorder NOS
  • New initiation or current treatment with quetiapine Immediate Release (IR)

Exclusion Criteria

  • Other psychotic disorders (e.g., due to medical condition)
  • Mental retardation (IQ lower than 70 points)

Outcomes

Primary Outcomes

Time to Service Disengagement

Time Frame: 12 months

The primary outcome of the study was the time to service disengagement (SD). This primary aim was chosen because the assertive approach of ACT is to prevent service disengagement3 and because service disengagement is a major predictor for relapse and thereby poor long-term outcome.16,17 Service disengagement was present, if a patient repeatedly refuses further treatment despite several attempts of reengagement (phone calls of patient and family in both treatment arms and potentially home visits in the ACT group).

Secondary Outcomes

  • Improvements of symptoms, functioning, quality of life, and satisfaction with care from patients and relatives perspectives(12 months)

Study Sites (1)

Loading locations...

Similar Trials